Roundtable with key actors in medicinal cannabis in Spain, aiming to address— from a scientific and regulatory perspective— the challenges and opportunities that this plant offers. The roundtable will explore the potential of the autonomous communities to promote regulatory frameworks that guarantee access to unregistered medicines derived from non-patentable herbal plants, and will analyze the contradictions that cannabis creates in the pharmaceutical field.
Miguel Torres, Senior Counsel at Baker Tilly
A lawyer since 1987, he has served as Senior Counsel at Baker Tilly Abogados since 2016. He has developed an extensive career in corporate, contractual and regulatory advisory work and in foreign investment, and has been cited as an expert in the cannabis regulatory field for assisting several companies in obtaining cultivation authorizations for research, scientific and medical purposes from the Spanish Agency of Medicines and Medical Devices (AEMPS). In this context, his experience is especially valuable for understanding regulatory, compliance and emerging business structure challenges in the medicinal cannabis sector in Spain.
Iker Val, CEO of Sovereign Fields
Activist and entrepreneur with more than 25 years in the cannabis movement. Founder of the Ganjazz Art Club in San Sebastián and a pioneer in developing the Cannabis Social Club model in the Basque Country. He has been active in cannabis policy reform as a board member of the National Federation and the Basque Federation, as well as the Responsible Regulation platform. In 2012 he created the Renovatio Foundation, from which he promoted social research, published several reports and organized the International Cannabis Forum for seven years. In 2018 he co-founded Sovereign Fields, currently operating in the United States and Europe. His work integrates activism, research and entrepreneurship, with a firm commitment to an ethical and sustainable cannabis culture.
Dr. Guillermo Moreno, Scientific Director of Khiron Sciences
His doctoral research led to the discovery of a new mechanism by which cannabinoids modulate pain signals before they reach the spinal cord, and enabled the characterization of a new class of potent analgesic compounds that do not cross the blood-brain barrier. He has worked as a cannabis research consultant for institutions such as the U.S. National Academies of Sciences and has developed R&D solutions for leading companies in the sector.
Dr. Carlo Ferreiro, CEO of Phytoplant
Holds a degree and PhD in Analytical Chemistry from the University of Córdoba, specialized in developing analytical platforms in metabolomics. He complemented his training with studies in industrial quality, pharmaceutical processes, environment, safety and laboratory management. He has participated in research projects at the University of Córdoba and at IMIBIC, focused on creating new analytical platforms, valorizing agri-food waste and studying bioactive compounds from medicinal plants. Author of more than twenty publications in high-impact scientific journals, he has extensive experience in national and international conferences.